Natural Medicines Targeting Mitochondrial Dysfunction in Spinocerebellar Ataxia Type 3: A Narrative Review of Cellular and Molecular Events
5 affiliations
- 1Department of Anatomy, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia
- 2Department of Forensic Medicine, Sarawak General Hospital, Jalan Hospital, Kuching 93586, Sarawak, Malaysia
- 3Unit of Biochemistry, Faculty of Medicine, MAHSA University, Jalan SP2, Bandar Saujana Putra, Jenjarom 42610, Selangor, Malaysia
- 4Center of Excellence for Brain Health and Neurotechnology, Academy of Life and Natural Sciences, Xi’an Jiaotong-Liverpool University, Suzhou 215123, China
- 5Department of Transfusion Medicine and Clinical Microbiology, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand
Abstract
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is the most common autosomal dominant spinocerebellar ataxia and is characterized by progressive neurodegeneration for which no Food and Drug Administration (FDA)-approved therapeutics are currently available. Mitochondrial dysfunction has emerged as a central pathogenic mechanism in SCA3, making it a promising therapeutic target. This narrative review aims to evaluate the published evidence on the therapeutic potential of natural medicines and their active compounds targeting mitochondrial dysfunction in SCA3. This review summarizes published evidence on the therapeutic potential of natural medicines and their active compounds targeting mitochondrial dysfunction in SCA3 in preclinical studies. The reviewed studies suggest the therapeutic potential of Glycyrrhiza inflata, Codonopsis pilosula, Ginkgo biloba, Poria cocos, Pueraria lobata, Rehmannia glutinosa, Curcuma longa, Hericium erinaceus, Astragalus membranaceus, Hemerocallis citrina, caffeic acid, and resveratrol in targeting mitochondrial dysfunction in SCA3. These natural medicines were reported to regulate multiple mitochondrial-associated pathways, including oxidative stress, mitochondrial membrane potential, mitochondrial bioenergetics, mitochondrial dynamics, mitochondrial quality control, and mitochondria-mediated apoptosis, thereby improving neuronal survival and mitochondrial function in experimental SCA3 models. In conclusion, natural medicines targeting mitochondrial dysfunction represent promising preclinical candidates for further investigation in SCA3. However, further mechanistic investigations, well-designed clinical trials, and optimization of pharmacokinetic properties are required to facilitate their translation into clinical practice.
Related
- Isoquercitrin ameliorates chondrocyte dysfunction in osteoarthritis by targeting AKT1-mediated mitochondrial dynamics regulation
- Modulation of mGluR1 signaling improves Purkinje cell dysfunction associated with spinocerebellar ataxia 14
- Emodin induces defensive autophagy against white spot syndrome virus infection via targeting the hemocyanin-mediated endoplasmic reticulum-mitochondrial crosstalk in shrimp
- Single-cell atlas reveals NLRP2 associated mitochondrial dysfunction in estrogen induced Macrobrachium nipponense sex reversal
- Mitochondrial dysfunction plays a key role in premature musculoskeletal aging in hypochondroplasia mouse model
BibTeX
@article{kmail2026natural,
title = {{Natural Medicines Targeting Mitochondrial Dysfunction in Spinocerebellar Ataxia Type 3: A Narrative Review of Cellular and Molecular Events}},
author = {Mwafaq Kmail and Noor Asyikin Suaidi and Jin Han Chin and Lee Wei Lim and Kah Hui Wong},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219623},
url = {https://www.mdpi.com/1422-0067/27/21/9623},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Natural Medicines Targeting Mitochondrial Dysfunction in Spinocerebellar Ataxia Type 3: A Narrative Review of Cellular and Molecular Events
AU - Mwafaq Kmail
AU - Noor Asyikin Suaidi
AU - Jin Han Chin
AU - Lee Wei Lim
AU - Kah Hui Wong
PY - 2026
DA - 2026/10/27
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219623
UR - https://www.mdpi.com/1422-0067/27/21/9623
AB - Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is the most common autosomal dominant spinocerebellar ataxia and is characterized by progressive neurodegeneration for which no Food and Drug Administration (FDA)-approved therapeutics are currently available. Mitochondrial dysfunction has emerged as a central pathogenic mechanism in SCA3, making it a promising therapeutic target. This narrative review aims to evaluate the published evidence on the therapeutic potential of natural medicines and their active compounds targeting mitochondrial dysfunction in SCA3. This review summarizes published evidence on the therapeutic potential of natural medicines and their active compounds targeting mitochondrial dysfunction in SCA3 in preclinical studies. The reviewed studies suggest the therapeutic potential of Glycyrrhiza inflata, Codonopsis pilosula, Ginkgo biloba, Poria cocos, Pueraria lobata, Rehmannia glutinosa, Curcuma longa, Hericium erinaceus, Astragalus membranaceus, Hemerocallis citrina, caffeic acid, and resveratrol in targeting mitochondrial dysfunction in SCA3. These natural medicines were reported to regulate multiple mitochondrial-associated pathways, including oxidative stress, mitochondrial membrane potential, mitochondrial bioenergetics, mitochondrial dynamics, mitochondrial quality control, and mitochondria-mediated apoptosis, thereby improving neuronal survival and mitochondrial function in experimental SCA3 models. In conclusion, natural medicines targeting mitochondrial dysfunction represent promising preclinical candidates for further investigation in SCA3. However, further mechanistic investigations, well-designed clinical trials, and optimization of pharmacokinetic properties are required to facilitate their translation into clinical practice.
SN - 1422-0067
ER -